Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
    • الموضوع:
      Patient Reported Outcome Measures* ; Quality of Life*; Antigens, CD19/*therapeutic use ; Immunotherapy, Adoptive/*adverse effects ; Lymphoma, Large B-Cell, Diffuse/*therapy; Antigens, CD19/adverse effects ; Anxiety/chemically induced ; Attention/drug effects ; Biological Products ; Diarrhea/chemically induced ; Fatigue/chemically induced ; Feeding and Eating Disorders/chemically induced ; Female ; Humans ; Male ; Middle Aged ; Pain/chemically induced ; Physical Functional Performance ; Time Factors ; Xerostomia/chemically induced
    • نبذة مختصرة :
      Chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel (axi-cel) has considerably improved survival in adults with relapsed/refractory large B-cell lymphoma. This study reports patient-reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days after treatment. Hematologic cancer patients treated with axi-cel (N = 103, mean age = 61, 39% female) completed SF-36 or PROMIS-29 QOL questionnaires prior to treatment and 90 days after. PRO-Common Terminology Criteria for Adverse Events toxicity items were completed by patients at baseline and 14, 30, 60, and 90 days after treatment. Mixed models examined change in PROs over time. From preinfusion to 90 days later, patients reported improvements in physical functioning, pain, and fatigue (ps < 0.01), but worsening of anxiety (p = 0.02). Patient-reported toxicities worsened by day 14 with improvement thereafter. The five most severe symptoms at day 14 included fatigue, decreased appetite, dry mouth, diarrhea frequency, and problems with concentration. Results indicate improvement in some domains of QOL over time with transient patient-reported toxicities.
      (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
    • References:
      Blood Adv. 2020 Feb 25;4(4):629-637. (PMID: 32074277)
      Qual Life Res. 2018 Jul;27(7):1885-1891. (PMID: 29569016)
      Biol Blood Marrow Transplant. 2013 Mar;19(3):450-9. (PMID: 23253558)
      Biol Blood Marrow Transplant. 2020 Jan;26(1):34-43. (PMID: 31605820)
      Biol Blood Marrow Transplant. 2017 Nov;23(11):1974-1979. (PMID: 28797784)
      J Clin Oncol. 2004 Sep 1;22(17):3485-90. (PMID: 15337796)
      Support Care Cancer. 2015 Dec;23(12):3645-52. (PMID: 26314706)
      Blood. 2016 Jun 30;127(26):3321-30. (PMID: 27207799)
      Blood. 2017 Oct 19;130(16):1800-1808. (PMID: 28774879)
      Nat Rev Clin Oncol. 2016 May;13(5):319-25. (PMID: 26787278)
      Cancer. 2018 Feb 15;124(4):841-849. (PMID: 29072787)
      Lancet Oncol. 2019 Jan;20(1):31-42. (PMID: 30518502)
      Biol Blood Marrow Transplant. 2019 May;25(5):e155-e162. (PMID: 30500439)
      JAMA Otolaryngol Head Neck Surg. 2016 Jun 1;142(6):517-23. (PMID: 27149571)
      Am J Manag Care. 2008 Aug;14(8):530-9. (PMID: 18690769)
      Biol Blood Marrow Transplant. 2016 Nov;22(11):2077-2083. (PMID: 27538374)
      Cancer. 2016 Apr 15;122(8):1290-7. (PMID: 26814442)
      Psychol Assess. 2014 Jun;26(2):513-27. (PMID: 24548149)
      Cancer. 2016 Jan 1;122(1):91-8. (PMID: 26439325)
      JAMA Oncol. 2015 Nov;1(8):1051-9. (PMID: 26270597)
      Support Care Cancer. 2008 Nov;16(11):1243-54. (PMID: 18322708)
      J Natl Cancer Inst. 2011 Dec 21;103(24):1851-8. (PMID: 22157640)
      Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. (PMID: 30592986)
      Lancet Oncol. 2018 May;19(5):e267-e274. (PMID: 29726391)
      Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. (PMID: 28925994)
      Clin Cancer Res. 2016 Apr 1;22(7):1553-8. (PMID: 26758559)
      Med Care. 2003 May;41(5):582-92. (PMID: 12719681)
      Qual Life Res. 2016 Mar;25(3):535-46. (PMID: 26577763)
      Lancet Oncol. 2019 Dec;20(12):1710-1718. (PMID: 31606419)
      N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
    • Grant Information:
      P30 CA762292 United States NH NIH HHS; R25 CA090314 United States CA NCI NIH HHS; K23 CA201594 United States CA NCI NIH HHS
    • Contributed Indexing:
      Keywords: behavioral science; hematological cancer; lymphoma; quality of life
    • الرقم المعرف:
      0 (Antigens, CD19)
      0 (Biological Products)
      U2I8T43Y7R (axicabtagene ciloleucel)
    • الموضوع:
      Date Created: 20210228 Date Completed: 20210719 Latest Revision: 20211204
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC7957158
    • الرقم المعرف:
      10.1002/cam4.3664
    • الرقم المعرف:
      33641257